Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Regarding R+F discontinued deal

<< Previous

Bullboard Posts

Next >>

Post by forhandlarenon Jan 16, 2023 9:38am

293 Views

Post# 35225346

Regarding R+F discontinued deal

The R+F deal wasn't important from a financial point of view. The NR today that informs that the deal has been discontinued is therefore not that bad, but it will be interesting to get more information tomorrow at the Q&A.

Interesting enough, R+F was never listed as a partner at the Sirona Biochem web page after the overhaul of of the design - so was this a consequence of the AbbVie deal?

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta